House Subcommittee to Hold Hearing on New TSCA Reform Bill

On January 22, 2026, at 2pm ET, the House Energy and Commerce Committee’s Environment Subcommittee will hold a hearing to examine newly released Toxic Substances Control Act (TSCA) reform legislation.

The hearing, titled “Chemicals in Commerce: Legislative Proposal to Modernize America’s Chemical Safety Law, Strengthen Critical Supply Chains, and Grow Domestic Manufacturing,” will focus on a discussion draft released on January 15, 2026.  No witnesses are currently listed on the hearing webpage.

The discussion draft would make structural changes to key provisions of the statute, including revisions to TSCA section 4 testing requirements, section 5 new chemical reviews, and section 6 reviews of existing chemicals.  It would also reauthorize EPA’s authority to collect fees from manufacturers, which is set to expire later this year.

“Targeted and measured reforms [to TSCA] will increase accountability, strengthen domestic manufacturing, and safeguard the health and safety of our communities,” said House Energy and Commerce Committee Chairman Brett Guthrie (R-KY-02) and Environment Subcommittee Chairman Gary Palmer (R-AL-06) in a joint statement.

“The legislation we’ll be discussing in this hearing would support these goals and help to ensure TSCA processes are working effectively to evaluate chemical safety and support American innovation,” they added.

A livestream of the hearing will be available online.

House Science Committee to Hold January 8 Hearing on Chemical Regulation

On January 8, 2026, at 10am ET, the House Committee on Science, Space, and Technology will hold a hearing entitled “Chemistry Competitiveness: Fueling Innovation and Streamlining Processes to Ensure Safety and Security.”

According to Inside EPA, the committee said in an announcement that the hearing will “examine the state of chemical research and development in the United States and how the regulatory environment affects progress.”  It comes after an October Senate Environment and Public Works Committee hearing on chemical regulation, which included substantial discussion regarding possible Toxic Substances Control Act (TSCA) reform.

The hearing will feature the following witnesses:

  • Charlotte Bertrand, Senior Director, Chemical Management, Regulatory Policy and Strategy, American Chemistry Council
  • Stan Meiburg, Former Acting Deputy Administrator, United States Environmental Protection Agency
  • Gwen Gross, Ph.D., Senior Technical Fellow, The Boeing Company
  • Keith Corkwell, Senior Vice President and President of Lubrizol Additives, The Lubrizol Corporation

A livestream of the hearing will be available on YouTube.

New Mexico to Hold Hearing on PFAS in Products Rulemaking

Beginning February 23, 2026, at 9am MT, the New Mexico Environmental Improvement Board (EIB) will hold a hybrid public hearing to consider the adoption of a proposed rule to implement the state’s PFAS in products law.  EIB is currently accepting public comments in advance of the hearing.

A previous post addressed the proposal’s novel PFAS labeling requirements, which would apply to all products with intentionally added PFAS beginning January 1, 2027.  In addition to labeling, the proposed rule implements statutory product prohibitions, establishes manufacturer reporting obligations, and outlines the process for manufacturers to obtain “currently unavoidable use” (CUU) designations from the New Mexico Environment Department (NMED).

Much of the proposed rule closely tracks the underlying statute, HB 212.  However, the statute merely authorized—rather than required—labeling requirements, and left the CUU framework unspecified.  The proposed rule fills in those gaps.

Product Bans

The proposed rule implements HB 212’s phased-in product bans.  Beginning January 1, 2027, New Mexico will prohibit the sale of the following products with intentionally added PFAS:

  • Cookware
  • Food packaging
  • Dental floss
  • Juvenile products
  • Firefighting foam

On January 1, 2028, the prohibition will expand to include:

  • Carpets or rugs
  • Fabric treatments
  • Feminine hygiene products
  • Textiles
  • Textile furnishings
  • Ski wax
  • Upholstered furniture

Finally, beginning in 2032, the prohibition will apply to all products except:

  • Products exempt from regulation under HB 212 (such as used products, medical devices, and veterinary products); and
  • Uses that EIB designates as CUUs.

Although HB 212 authorizes the EIB to add additional product categories to the 2027 and 2028 bans, the proposed rule limits prohibitions to those required by the statute.

Manufacturer Reporting Requirements

On or before January 1, 2027, HB 212 requires manufacturers that sell products containing intentionally added PFAS to submit the following information to NMED:

  • A brief description of the product;
  • The purpose of the PFAS in the product;
  • The amount of each PFAS in the product by exact quantity or concentration range;
  • Manufacturer and contact information; and
  • Any other information requested by NMED.

Manufacturers must update their submissions within 30 days of a significant change.  The proposed rule defines “significant change” as the intentional addition of a new PFAS, a 10% or greater increase in the concentration of PFAS, or a change in responsible official or contact information.

The proposed rule sets a fee of $2,500 for the initial report and $1,000 for each subsequent significant change report, with fees adjusted for inflation.  It also establishes procedures for requesting reporting deadline extensions or waivers where substantially equivalent information is already publicly available.

Under HB 212, reporting obligations do not apply to products that are statutorily exempt or that have received a CUU designation.

Currently Unavailable Uses (CUUs)

To avoid prohibition of a product containing intentionally added PFAS, the proposed rule would allow a manufacturer—or a group of manufacturers—to submit a proposal to NMED requesting a CUU designation.  A separate proposal would be required for each individual combination of product category and associated industrial sector.

CUU proposals would generally be due at least 12 months before the effective date of the applicable sales prohibition.  For products subject to the January 1, 2027 prohibition, however, CUU proposals submitted by October 31, 2026 would be deemed approved pending NMED review.

The proposed rule would require that CUU proposals include:

  • Identification of the specific PFAS intentionally added to the product;
  • A brief description of the product;
  • An explanation of why the PFAS use “is essential for health, safety or the functioning of society”;
  • A description of how the PFAS is essential to the product’s function;
  • A description of whether alternatives for the specific use of PFAS are available;
  • A list of applicable federal and state regulations governing the product due to its intentional use of PFAS, including any sales prohibitions;
  • If the product is prohibited or lacks a CUU determination in another jurisdiction, a list of comparable products that remain on the market in that jurisdiction;
  • Where similar products are available despite a comparable prohibition, a justification for why those products are not reasonably available alternatives or documentation demonstrating that they would not perform as intended in New Mexico;
  • Contact information; and
  • Any known or reasonably ascertainable information regarding the human health or environmental impacts of PFAS in the product.

Most of these categories include additional, detailed information requests.  For example, when identifying comparable regulatory programs in other jurisdictions, submitters must specify whether the prohibition is absolute or includes a CUU-like process and, if so, whether the submitter has applied under that program and the status of the application.

CUU designations would expire three years after approval unless a manufacturer submits a new CUU proposal.  The proposed rule establishes a $5,000 fee for an initial CUU application and a $2,500 fee for renewals, with fees adjusted for inflation.

For CUU proposals related to the 2027 prohibitions, NMED would issue final determinations by March 1, 2027.  A list of approved CUUs would be made available on NMED’s website.

Testing and Enforcement

HB 212 authorizes NMED to require manufacturers to test products if the department has reason to believe that a product contains intentionally added PFAS.  The proposed rule sets a threshold for PFAS of 100 parts per million (ppm).  If test results exceed that threshold, the manufacturer would be required to submit an initial report and, if the product is prohibited, notify distributors and retailers.

Manufacturers that violate HB 212 or its implementing regulations may be subject to civil penalties of up to $15,000.  NMED may also assess administrative costs incurred in enforcing the statute and rules for each day a violation occurs.

More information about HB 212, also known as the PFAS Protection Act, is available on NMED’s website.

Senate EPW Committee to Examine the Future of PFAS Cleanup and Disposal

On November 19, 2025, at 10am, the Senate Committee on Environment and Public Works (EPW) will hold a hearing to “Examine the Future of PFAS Cleanup and Disposal Policy.”

The hearing will include the following panelists:

  • Eric Gerstenberg, Co-CEO of Clean Harbors, an environmental and industrial services company
  • Leah Pilconis, General Counsel of Associated General Contractors of America
  • Kate R. Bowers, Supervisory Attorney at the Congressional Research Service

Clean Harbors conducted a PFAS incineration study in 2024 in conjunction with EPA and the Defense Department (DOD).  According to EPA, the incinerator’s tested PFAS destruction and removal efficiencies “ranged from 99.95 to 99.9999 percent.”

The study followed procedures outlined in EPA’s 2024 interim guidance on PFAS destruction and disposal, discussed in a previous post.  EPA must update this guidance as necessary and at least every three years.  The forthcoming hearing is likely to shape the direction of those updates.

EPW to Hold October 23 Hearing on Chemical Regulation

The Senate Committee on Environment and Public Works (EPW) will hold a hearing on chemical regulation this week, offering potential insight into Toxic Substances Control Act (TSCA) reform legislation reportedly being developed in the Senate.

The hearing, titled “Examining the Beneficial Use and Regulation of Chemicals,” is scheduled for 10:30am on October 23, 2025.  It will be convened by EPW’s Chemical Safety Subcommittee, which is chaired by Senator John Curtis (R-Utah).

According to EPW’s website, the hearing will include the following panelists:

  • Peter Huntsman, President and CEO of Huntsman Corporation, a chemical manufacturer.
  • Gwen Gross, Senior Technical Fellow at The Boeing Company.
  • Tracey Woodruff, Professor and Director of the Program on Reproductive Health and the Environment at the University of California, San Francisco. Dr. Woodruff previously worked as a scientist at EPA.

The hearing was originally scheduled for July but was postponed.

New Mexico to Hold Webinar on PFAS Labeling on September 25

On September 25, 2025, the New Mexico Environment Department (NMED) will hold an informational webinar on product labelling requirements for PFAS at 1pm MT (3pm ET).  To register, email NMED-PFAS@env.nm.gov.

Under HB212, enacted in April 2025, NMED is authorized to adopt rules requiring that manufacturers label products containing PFAS.  Earlier this month, New Mexico’s Environmental Secretary reportedly told lawmakers that NMED would soon release draft regulations to implement HB 212, including labeling requirements.

PFAS Restrictions and Reporting Under HB 212
  • Labeling authority: NMED may require PFAS labeling.
  • Phased bans: Restrictions on intentionally added PFAS begin in 2027, expand to more product types in 2028, and culminate in a ban on most products in 2032. Exemptions apply for certain products, such as medical devices, and for uses designated by NMED as “currently unavoidable.”
  • Reporting requirement: By January 1, 2027, manufacturers must report information on intentionally added PFAS, including purpose of use and amount (by CASRN).

More details are available on NMED’s PFAS webpage.

Verdant Law to Lead ACA Webinar on FTC’s “Made in the USA” Enforcement

Verdant Law is pleased to announce that Phil Moffat and Irene Hantman will lead an American Coatings Association (ACA) webinar on the FTC’s renewed focus on “Made in the USA” claims.  The session will be held on September 25, 2025, from 1–2pm ET.

Although the current Trump administration has generally adopted a deregulatory stance, “Made in the USA” claims have been a notable exception.  This past July, the FTC declared “Made in the USA Month” and announced stepped-up enforcement, including warning letters to major retailers such as Amazon and Walmart.

This webinar will provide insight to help attendees align marketing strategies with legal standards, avoid enforcement risks, and ensure “Made in the USA” claims are both effective and compliant.

Attendance is limited to, but free for, ACA members.  Register here.

Phil Moffat to Present at Chemical Watch Regulatory Summit North America 2025

Verdant Law is pleased to announce that Phil Moffat will speak at Chemical Watch’s Regulatory Summit North America 2025, which will take place September 15–18 in Alexandria, Virginia.

On September 15 at 11:50 am, Mr. Moffat will present on the Trump administration’s implementation of the Toxic Substances Control Act (TSCA) New Chemicals Program.  At 12:40 pm, Mr. Moffat will join an extended Q&A panel titled “Stakeholder perspectives on new chemical trends.”

Registration for the summit is open for both in-person and virtual attendance.

Update – September 16, 2025

Slides from Mr. Moffat’s presentation, “Balancing Innovation and Risk Management: TSCA’s New Chemical Review Process,” are now available here.

Irene Hantman to Present at Chemical Watch Summit in September

Verdant Law is pleased to announce that Irene Hantman will present on litigation over green marketing claims at Chemical Watch’s Regulatory Summit North America 2025.

Ms. Hantman’s September 18 presentation will cover noteworthy recent cases, including suits against manufacturers of everyday consumer products over alleged PFAS content.  The presentation will also discuss possible impacts from state-level PFAS disclosure laws, which may lead to a floodgate of new lawsuits.

Following the 3:05pm presentation, Ms. Hantman will be joined by other experts for a Q&A session.

The Regulatory Summit will be held in Alexandria, Virginia, from September 15–18.  Virtual attendance options are available.

Update – November 11, 2025

Slides from Ms. Hantman’s presentation, “Green Marketing Claims, PFAS, and Litigation,” are now available here.

Fifth Circuit Questions EPA’s Methylene Chloride Rule in Landmark TSCA Case

On June 3, 2025, the Fifth Circuit heard oral argument in a case consolidating industry and Sierra Club challenges to EPA’s regulation of methylene chloride under the Toxic Substances Control Act (TSCA).  The panel generally appeared to doubt EPA’s justification for banning certain uses of the solvent and imposing stringent workplace restrictions.

The background for East Fork Enterprises Inc. v. EPA, No. 24-60256, is discussed in a previous blog post.  It looks likely that this will be the first case in which a court of appeals rules on the merits of a TSCA risk management rule since EPA was granted expanded authority to regulate existing chemicals with the 2016 Lautenberg amendments to TSCA.

Undefended Policies

The industry petitioners’ attorney urged the court to rule on two Biden-era policies that the Trump EPA has declined to defend: the agency’s decision not to assume that workers use PPE, and its “single determination” approach to findings of unreasonable risk.

One judge asked the industry attorney whether there had been any statistical surveys or epidemiological work to determine the number of workers affected by methylene chloride, suggesting that EPA should base its review in terms of “reality.”  The industry attorney replied that isolated incidents were noted in the record, but that they should be considered against the size of the country.  “That there have been a given number of incidents is not enough to tell you the scale of the risk,” he said.

When a judge suggested that EPA’s use of conservative “uncertainty factors” helps the agency extrapolate from human studies in a way that “protect[s] those…most at risk,” the industry attorney pushed back.  “The uncertainty factors are going far beyond that…it is protective factor times protective factor times protective factor, and they’re doing that in a part of the analysis that is quite separate from what they’re doing for vulnerable populations,” he said.

Another judge inquired about the economics of the methylene chloride industry, claiming that “it’s not irrelevant to understand what the scope of the market is” when determining whether a regulation is reasonable.

Scientific Evidence

To defend its decision to impose significantly stricter worker exposure limits than OSHA, EPA argued that OSHA’s standard was based on cancer findings, rather than “the most common adverse effect, adverse liver effects.”  This drew pushback from one judge, who claimed that liver effects had only been found in animals, not humans.

“If you’re going to really show that there’s toxicity to the liver, it seems to me that you have to show toxicity to the liver, and that requires epidemiological testing, doesn’t it?” the judge said.  “EPA is tasked with finding unreasonable risk, and unreasonable risk, from a scientific standpoint, when you’re talking about humans, is epidemiology.”

EPA’s attorney acknowledged that “human studies are the first place you look” but said that “when [EPA doesn’t] have concrete information, they have to look [to] animals.”  Earlier in the argument, EPA’s attorney noted that animal testing allows for dissection, unlike human studies—which she argued can make some effects, like the early stages of liver disease, more apparent.

Both EPA and Sierra Club also pointed to the Lautenberg amendments’ explicit directive that EPA consider worker risks as evidence that Congress did not intend for EPA to defer to OSHA’s existing limitations.

I Survived”

In a notable exchange, one judge expressed concern with the breadth of the risk management rule: “It’s hard to say that any party can verify that they have never given a bit of methylene chloride to their friend who’s refinishing old furniture, a subject for which I’m particularly sensitive, because I’ve done it, and I survived.”

EPA’s attorney replied that the rule permits continued use of methylene chloride for furniture refinishing for another five years because no adequate alternative currently exists.  “This is not a case where EPA was just unilaterally deciding, ‘we don’t like this chemical, we’re going to regulate so there’s zero risk,’” she said.

EPA was also sharply pressed on the applicable standard of review.  “We noticed that EPA’s brief didn’t cite a single case that relied on the substantial evidence standard [used by TSCA] as opposed to the lower arbitrary and capricious standard,” a judge observed.

Sierra Club Arguments

The panel also appeared skeptical about the Sierra Club’s arguments, which claim that EPA’s regulations did not properly protect fenceline communities or address risks to the ozone layer.

“It’s a very, very, very, stringent regulation…I mean, what do you mean?” one judge asked.

When EPA noted that methylene chloride emissions are regulated under the Clean Air Act, one judge asked, “How does Sierra Club have a justification for coming in on this regulation at all, vis-à-vis fenceline communities, because this regulation does not cover ambient air emissions?”

EPA’s attorney responded that this was why risks to fenceline communities were not evaluated in the original 2020 risk evaluation for methylene chloride—though those risks were considered in a 2022 revision.

During rebuttals, the Sierra Club was also pressed about EPA’s one-in-a-million cancer benchmark.  “One in a million is pretty darn small…where’s the science that supports one in a million of anything being unreasonable?” one judge asked.

The Sierra Club’s attorney said that the benchmark was supported by the Science Advisory Committee on Chemicals (SACC), prompting the judge to respond, “We did a little looking at that, and it looked like some…members of the [SACC] had also themselves received EPA grants.”

But the Sierra Club argued that it does create a conflict of interest, because other members had been funded by methylene chloride manufacturers.  “I think EPA aims for a diverse range of views on the SACC,” its attorney said.